Although pamiparib previously demonstrated antitumor activity in cell lines with breast cancer genes 1/2 (BRCA1/2) mutations or other homologous recombination deficiencies [22], its effect on homologous recombination deficiency was not assessed in the current study. This evidence concerns the gene BRCA1 and breast carcinoma.